This summary was created by AI, based on 3 opinions in the last 12 months.
Entrada Therapeutics, Inc. (TRDA-Q) has been recommended as a top pick by Stockchase Research Editors, with the company triggering its stop at $16 resulting in a net investment gain of 12%. The clinical stage pharma company produces drugs that aid in the delivery of other therapeutics and has a portfolio of RNA based programs. It trades at a low earnings multiple, under book value, and supports a 32% ROE with growing cash reserves. Analysts’ price target is $21.50, offering an upside potential of 27% from the stop-loss set at $13.
Entrada Therapeutics, Inc. is a American stock, trading under the symbol TRDA-Q on the NASDAQ (TRDA). It is usually referred to as NASDAQ:TRDA or TRDA-Q
In the last year, 2 stock analysts published opinions about TRDA-Q. 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Entrada Therapeutics, Inc..
Entrada Therapeutics, Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Entrada Therapeutics, Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Entrada Therapeutics, Inc. published on Stockchase.
On 2025-01-14, Entrada Therapeutics, Inc. (TRDA-Q) stock closed at a price of $12.49.
Our PAST TOP PICK with TRDA has triggered its stop at $16. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 12%, when combined with our previous guidance.